Mr. Stephen Van Deventer reports

PREVECEUTICAL CLOSES INITIAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Preveceutical Medical Inc., further to its news release dated Sept. 28, 2026, has closed an initial tranche of its previously announced $600,000 non-brokered private placement, which initial tranche consisted of the issuance of 5.2 million units of the company at a price of three cents per unit for gross aggregate proceeds of $156,000. Preveceutical intends to close a second tranche for the remainder of the offering in the coming weeks.

Each unit comprises one common share in the capital of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of six cents per warrant share for a period of two years from the closing of the initial tranche, subject to an acceleration right, whereby the expiry date of the warrants may be accelerated if the daily closing price of the shares equals or exceeds 11 cents or greater on the Canadian Securities Exchange (or such other recognized securities exchange on which the shares may then trade) for a minimum of ten consecutive trading days, in which event the company may accelerate the expiry of the warrants by giving notice via news release and, in such case, all of the then unexercised warrants will expire on the 30th day after the date on which the news release is disseminated.

In connection with the initial tranche closing, the company paid an advisory commission fee of $12,480 to one eligible finder and issued 416,000 advisory commission warrants. The advisory commission warrants are exercisable into one additional share at an exercise price of six cents per share for two years from the initial tranche closing, subject to the acceleration right.

The company intends to use the aggregate gross proceeds from the sale of the offering for short loan repayments, audit, accounting and legal fees, patents, and further studies and analysis of rodents and tissues, and general working capital purposes.

All securities issued in relation to the initial tranche are subject to a hold period expiring four months and one day after the initial tranche closing, in accordance with applicable securities laws.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.